AU2021377891A1 - Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors - Google Patents

Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors Download PDF

Info

Publication number
AU2021377891A1
AU2021377891A1 AU2021377891A AU2021377891A AU2021377891A1 AU 2021377891 A1 AU2021377891 A1 AU 2021377891A1 AU 2021377891 A AU2021377891 A AU 2021377891A AU 2021377891 A AU2021377891 A AU 2021377891A AU 2021377891 A1 AU2021377891 A1 AU 2021377891A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
represented
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021377891A
Other languages
English (en)
Other versions
AU2021377891A9 (en
Inventor
Andrew George CAPACCI
TeYu CHEN
Felix Gonzalez Lopez De Turiso
Martin HIMMELBAUER
Brian T. Hopkins
John Howard Jones
Edward Yin-Shiang Lin
Bin Ma
Isaac Marx
Marta Nevalainen
Vatee Pattaropong
Robin Prince
Thomas Purgett
Jurgen Schulz
Simone SCIABOLA
George VANDEVEER
Zain YOUSAF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2021377891A1 publication Critical patent/AU2021377891A1/en
Publication of AU2021377891A9 publication Critical patent/AU2021377891A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021377891A 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors Pending AU2021377891A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063113515P 2020-11-13 2020-11-13
US63/113,515 2020-11-13
PCT/US2021/059168 WO2022104079A1 (en) 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors

Publications (2)

Publication Number Publication Date
AU2021377891A1 true AU2021377891A1 (en) 2023-07-06
AU2021377891A9 AU2021377891A9 (en) 2024-04-18

Family

ID=78828007

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021377891A Pending AU2021377891A1 (en) 2020-11-13 2021-11-12 Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors

Country Status (14)

Country Link
US (1) US20240083900A1 (https=)
EP (1) EP4244223A1 (https=)
JP (1) JP7839790B2 (https=)
KR (1) KR20230119134A (https=)
CN (1) CN116783199A (https=)
AR (1) AR124048A1 (https=)
AU (1) AU2021377891A1 (https=)
BR (1) BR112023009116A2 (https=)
CL (1) CL2023001367A1 (https=)
CO (1) CO2023007677A2 (https=)
MX (1) MX2023005626A (https=)
TW (1) TW202233624A (https=)
UY (1) UY39517A (https=)
WO (1) WO2022104079A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086575A1 (en) * 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形
WO2024083111A1 (zh) * 2022-10-18 2024-04-25 首药控股(北京)股份有限公司 一种新型杂环化合物
WO2024117205A1 (ja) * 2022-11-30 2024-06-06 北興化学工業株式会社 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤
CN116693357B (zh) * 2023-06-07 2026-01-27 西安工程大学 一种β-三氟甲基不饱和酰胺及其合成方法
WO2025049254A1 (en) * 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
CN118955332A (zh) * 2024-07-31 2024-11-15 德阳悦合生物医药科技有限公司 一种作为医药中间体的化合物叔丁基甲基(3-酮环丁基)氨基甲酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266908C (en) * 1996-09-27 2010-07-20 Joseph E. Saavedra O2-arylated or o2-glycosylated 1-substituted diazen-1-ium-1,2-diolates and o2-substituted 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
RS58361B1 (sr) * 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
WO2020114487A1 (en) * 2018-12-07 2020-06-11 Sunshine Lake Pharma Co., Ltd. Ret inhibitors, pharmaceutical compositions and uses thereof
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2025515728A (ja) * 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形

Also Published As

Publication number Publication date
CL2023001367A1 (es) 2024-01-05
JP2023549360A (ja) 2023-11-24
CO2023007677A2 (es) 2023-09-08
TW202233624A (zh) 2022-09-01
BR112023009116A2 (pt) 2023-10-03
CN116783199A (zh) 2023-09-19
AR124048A1 (es) 2023-02-08
MX2023005626A (es) 2023-07-31
KR20230119134A (ko) 2023-08-16
UY39517A (es) 2022-06-30
WO2022104079A1 (en) 2022-05-19
JP7839790B2 (ja) 2026-04-02
US20240083900A1 (en) 2024-03-14
EP4244223A1 (en) 2023-09-20
AU2021377891A9 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
AU2021377891A9 (en) Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors
US20240376104A1 (en) Bcl-2 Inhibitors
WO2024118966A1 (en) Glutarimide-containing pan-kras-mutant degrader compounds and uses thereof
WO2022235945A1 (en) Compounds for targeting degradation of bruton's tyrosine kinase
KR20260010430A (ko) Kras g12s 및 g12c 억제제
CA2932608A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2014261894A1 (en) Biheteroaryl compounds and uses thereof
TW202330548A (zh) 用於降解egfr激酶的化合物
KR102920418B1 (ko) 키나아제 억제 활성을 갖는 화합물
EP2928888A1 (en) Substituted pyridopyrazines as syk inhibitors
CA3234429A1 (en) Ras inhibitors, compositions and methods of use thereof
EP4429770A1 (en) Btk inhibitors
JP7779900B2 (ja) Ｂｔｋ阻害剤
JP2023508394A (ja) Ｂｔｋ阻害剤
RU2858502C2 (ru) Производные пиразол[1,5-a]пиразина в качестве ингибиторов втк
WO2023086575A1 (en) Btk inhibitors
CA3256816A1 (en) LRRK2 INHIBITORS

Legal Events

Date Code Title Description
SREP Specification republished